相关实验视频

Updated: Jun 28, 2025

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

在患有甲状腺眼病的患者中,teprotumumab可以改善光敏感性

Emanuil Parunakian¹, Shoaib Ugradar¹, Joseph Tolentino¹

¹Private Practice, Beverly Hills, CA, USA.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie

|April 19, 2024

概括

在患有甲状腺眼病 (TED) 的患者中,teprotumumab显著改善了光敏感性. 这种新的IGF-1R抗体治疗可以缓解急性和慢性TED症状,表明除了机械变化之外的机制.

科学领域:

眼科医生眼科眼科
内分泌学在内分泌学.
免疫学免疫学免疫学

背景情况:

甲状腺眼病 (TED) 是一种影响眼睛的自身免疫性疾病.
光敏感性是TED患者常见的和令人衰弱的症状.
现有研究缺乏关于teprotumumab对大型TED队列中的光敏感性影响的前性研究.

研究的目的:

为了前性地评估teprotumumab对急性和慢性TED患者光敏感性的影响.
为了评估teprotumumab治疗后视觉光敏感性问卷-8 (VLSQ-8) 评分的变化.
探索VLSQ-8改进和TED中的机械变化之间的关系.

主要方法:

九十名患有TED和光敏感性在基线的患者被纳入.
患者接受了teprotumumab治疗,VLSQ-8,proptosis,CAS,MRD1和MRD2在治疗前和后进行测量.
进行了统计分析,以确定VLSQ-8分数变化的意义.

主要成果:

采用teprotumumab治疗导致VLSQ-8总得分和所有子类别的得分显著降低 (p < 0.01).
80%的患者在至少一个VLSQ-8类别中经历了临床显著改善.
在急性和慢性TED组之间没有观察到VLSQ-8得分改善的显著差异.

结论:

在患有急性和慢性甲状腺眼病的患者中,teprotumumab有效地改善了光敏感性.
观察到的光敏感度的改善表明了独立于机械TED变化的潜在机制.
这项研究强调了teprotumumab在TED患者中减轻光恐惧症的潜力.

关键词:

轨道轨道的轨道.甲状腺是什么?甲状腺是什么?甲状腺眼睛疾病甲状腺眼病甲状腺眼部疾病治疗治疗治疗

更多相关视频

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Author Spotlight: Integrating Ultrasound Imaging with Biochemical Markers for Thyroid Disease Diagnosis

Published on: February 9, 2024

相关概念视频

Synthesis and Regulation of Thyroid Hormones

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...